Research programme: oral hBNP - Biocon
Alternative Names: BN-054; BNP 054; NBN 002; NBN 054; NBN 054 - BioconLatest Information Update: 16 Jul 2016
At a glance
- Originator Biocon
 - Class Natriuretic peptides
 - Mechanism of Action Diuretics
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 
Highest Development Phases
- No development reported Cardiovascular disorders
 - Discontinued Heart failure
 
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in India (PO)
 - 26 Sep 2005 Data presented at the 9th Annual Scientific Meeting of the Heart Failure Society of America (HFSA-2005) have been added to the Heart failure pharmacodynamics section
 - 30 Aug 2005 Nobex and Biocon have entered into an agreement to co-develop oral hBNP worldwide for for the treatment of heart failure and other portential cardiovascular disease indications